In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1857 News Items found
Dr. Mara Sherman in her lab, with two trainees working in the background
Into the Matrix: MSK’s Mara Sherman is Unlocking the Secrets of the Fibrotic Fortress that Surrounds and Protects Pancreatic Cancer

Dr. Mara Sherman's lab at the Sloan Kettering Institute is “all pancreas, all the time.” Learn how her research program is illuminating interactions between cancer cells and the dense weave of fibrous cells that surrounds and protects pancreatic tumors.
Dr. Rona Yaeger
FDA Approves First Colorectal Cancer Treatment that Targets G12C KRAS Gene

The targeted therapy adagrasib received accelerated approved for colorectal cancer caused by a mutation called KRAS-G12C, when used in combination with the drug cetuximab. MSK investigators have led much of the research that resulted in this combined drug approval.
Joseph Sun and Rebecca Delconte
Fasting Primes the Immune System’s Natural Killer Cells to Better Fight Cancer, New Study in Mice Finds

Animal model research from MSK has shown for the first time that fasting can reprogram the metabolism of natural killer cells, helping them to survive in the harsh environment in and around tumors, while also improving their cancer-fighting ability.
Dr. Alexander Drilon
FDA Grants Accelerated Approval to Repotrectinib for Cancers with NTRK Fusions 

The FDA has approved the targeted drug repotrectinib for patients 12 and older with tumors that carry gene changes called NTRK fusions. The trial that resulted in the approval was led by MSK investigators.
Sammy gets ready to swing a bat
MSK Earns Top Distinction for Pediatric Cancer Care From American College of Surgeons

Thanks to MSK’s expertise in treating young people with cancer, 16-year-old high school athlete Sammy is back to doing what he loves.
A masked nurse holds a card that says “thanks” in bright colors
2023 MSK Giving

In 2023, the MSK Giving community raised a record-breaking $1 billion — 100% of which will support our mission of ending cancer for life.
Seen are Scott Stuart, MSK Chair, Board of Trustees, and Selwyn M. Vickers, MD, FACS, President and CEO of MSK
A Message From MSK Leaders Selwyn M. Vickers and Scott Stuart

The President and CEO and Chair of the Board at Memorial Sloan Kettering Cancer Center introduce the year's highlights in their introductory letter to the 2023 Annual Report.
MSK biochemist and imaging specialist Kayvan Keshari and biomedical engineer Daniel Heller.
Education
A New Breed of Cancer Fighters

Read about a first-of-its kind PhD program that enables aspiring scientists to tackle tough cancer problems.
MSK patient Marc Scarduffa seen holding his dog at the beach.
Clinical Trials at MSK Aim To Reduce Side Effects of Cancer Treatment

Learn how MSK is Improving patients’ quality of life with less toxic treatments.
Male AML patient kneeling next to dog outside.
In the Clinic
Controlling a Relentless Leukemia

Read about new targets and tactics for treating acute myeloid leukemia.